Skip to main content
Download PDF

Correction: Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial)

BMC Cancer volume 24, Article number: 806 (2024) Cite this article

The Original Article was published on 30 May 2024

Correction: BMC Cancer 24, 661 (2024)

https://doi.org/10.1186/s12885-024-12415-2.

Following publication of the original article [1], it was reported that the third author, Clément Lahaye, was erroneously omitted from the author group. Clément Lahaye is affiliated with Unité mobile de Gériatrie, CHU Clermont-Ferrand, Clermont-Ferrand, France.

The author group above has been updated and the original article [1] has been corrected.

References

  1. Casile M, Albrand G, Lahaye C, et al. Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial). BMC Cancer. 2024;24:661. https://doi.org/10.1186/s12885-024-12415-2.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Biological Hematology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France

    Mélanie Casile, Benjamin Lebecque, Joévin Besombes, Céline Bourgne, Sandrine Saugues, Caroline Jamot & Marc G. Berger

  2. Geriatric Evaluation and Management unit, Antoine Charial Hospital, Francheville, Lyon, France

    Gilles Albrand

  3. EA 7453 CHELTER, University of Clermont Auvergne, Clermont-Ferrand, France

    Mélanie Casile, Benjamin Lebecque, Joévin Besombes, Céline Bourgne & Marc G. Berger

  4. Biostatistics Unit, Clinical Research and Innovation Department, CHU Clermont-Ferrand, Clermont-Ferrand, France

    Bruno Pereira

  5. Biological Resources Centre – Auvergne, CHU Clermont-Ferrand, Clermont-Ferrand, France

    Sandrine Saugues, Caroline Jamot & Marc G. Berger

  6. Clinical Hematology Department, CHU Clermont-Ferrand, Clermont-Ferrand, France

    Eric Hermet

  7. Unité mobile de Gériatrie, CHU Clermont-Ferrand, Clermont-Ferrand, France

    Clément Lahaye

Authors
  1. Mélanie Casile
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gilles Albrand
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Clément Lahaye
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Benjamin Lebecque
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Joévin Besombes
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Céline Bourgne
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bruno Pereira
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Sandrine Saugues
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Caroline Jamot
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Eric Hermet
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Marc G. Berger
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mélanie Casile.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The online version of the original article can be found at https://doi.org/10.1186/s12885-024-12415-2.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Casile, M., Albrand, G., Lahaye, C. et al. Correction: Value of combining biological age with assessment of individual frailty to optimize management of cancer treated with targeted therapies: model of chronic myeloid leukemia treated with tyrosine kinase inhibitors (BIO-TIMER trial). BMC Cancer 24, 806 (2024). https://doi.org/10.1186/s12885-024-12592-0

Download citation

  • Published:

  • DOI: https://doi.org/10.1186/s12885-024-12592-0

BMC Cancer

ISSN: 1471-2407

Contact us